Anti-SIGLEC6 antibody

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.

Activity summary

SIGLEC6 also known as CD327 is a protein found on some immune cells particularly on B cells and to a lesser extent on macrophages and dendritic cells. This protein has a molecular mass of around 100 kDa. As a member of the sialic acid-binding immunoglobulin-type lectins family (siglecs) SIGLEC6 mechanistically functions by recognizing and binding to specific sialic acid-containing carbohydrates on cell surfaces. This recognition influences cell-cell interactions and signaling processes important for immune response modulation.

Biological function summary

Four words that are not SIGLEC6 illustrate its involvement in immune system regulation. SIGLEC6 serves as an inhibitory receptor that helps dampen B cell receptor signaling balancing the immune response to prevent overactivation. It often partners with other proteins in complex cellular interactions within the immune cells. The expression of SIGLEC6 in placental tissues also suggests a role in trophoblast invasion and development although this function requires more research to fully understand the mechanisms involved.

Pathways

Four words that are not SIGLEC6 describe its integration into the immune signaling pathways particularly the immune response regulation. SIGLEC6 is a part of the B cell receptor signaling pathway acting as an inhibitory modulator. Through this pathway it connects with proteins like CD22 and other siglecs that contribute to the regulation of B cell activity. Additionally its role in glycan recognition links it to pathways associated with cell surface interactions and immune tolerance.

Associated diseases and disorders

Four words that are not SIGLEC6 highlight its relevance to certain conditions. SIGLEC6 expression alterations have implications in chronic lymphocytic leukemia (CLL) where it potentially influences disease progression by modulating B cell signaling. The protein has also been connected to gestational trophoblastic diseases potentially affecting placental development. In these contexts SIGLEC6 interacts with proteins such as CD22 in CLL where they collectively affect leukemic cell behaviors and disease outcomes.